Skip to content

Evaluation of intestinal hormones in healthy patients and in obese patients with and without type 2 diabetes through isoglycemic clamp before and after stomach reduction surgery

Evaluation of the incretin effect in healthy patients and in obese patients with and without type 2 diabetes through Isoglycemic Clamp before and after surgery (Biliopancreatic Diversion) or drug (Inhibitor of Dipeptidyl Peptidase IV [DPP-IV])

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5vsmm6
Enrollment
Unknown
Registered
2014-11-11
Start date
2011-03-25
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, obesity, bariatric surgery.

Interventions

Controlled study: one experimental group and two control groups. Experimental group: 10 obese grade I and II patients with type 2 diabetes who underwent biliopancreatic diversion surgery. Evaluated pr
Procedure/surgery

Sponsors

Universidade Estadual de Campinas
Lead Sponsor
Universidade Estadual de Campinas
Collaborator

Eligibility

Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 30 and 60 years, type 2 diabetic patients without medication for diabetes or who are not making use for at least 3 months; weight variation of less than 5% in the last three months; ability to understand the study procedures and voluntarily agree to participate in the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: Age under 30 and over 60, patients with type 2 diabetes using insulin, type 2 diabetics with poorly controlled diabetes (glycated hemoglobin A1c greater than 8.5%), BMI less than 18.5 kg / m²; history of liver disease such as cirrhosis or chronic active hepatitis; changing functions renal function (creatinine greater than 1.4 mg / dl in women and greater than 1.5 mg / dl in men) and hepatic ALT and / or AST 3 times above normal; recent history of malignancy (less than 5 years), use of injectable or oral steroids for more than 14 consecutive days in the past 3 months, or with some drug side effects on glucose metabolism.

Design outcomes

Primary

MeasureTime frame
Difference in the incretin effect evaluated by isoglycemic clamp technique in healthy, obese subjects with normal glucose tolerance and type 2 diabetic obese.;No statistical difference was found between the incretin effect of different groups.

Secondary

MeasureTime frame
Evaluation of the "incretin profile" evolution by isoglycemic clamp technique in the group of obese diabetic patients 1 and 12 months after surgery by the technique of biliopancreatic diversion.;Improvement on incretin effect one year after biliopancreatic diversion surgery assessed by isoglycemic clamp test.

Countries

Brazil

Contacts

Public ContactBruno Geloneze

Universidade Estadual de Campinas

bgeloneze@terra.com.br+55 (19) 3521 8589

Outcome results

None listed

Source: REBEC (via WHO ICTRP)